Revolution Medicines initiated at Morgan Stanley with overweight rating
Morgan Stanley initiated Revolution Medicines (NASDAQ: RVMD) with an overweight rating. The firm set a $255 price target, citing the company’s pipeline of RAS(“ON”) inhibitors.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.